PACTR202207762785564Other3 期
Evaluation of the Efficacy, safety, and tolerability of Difluprednate 0.05% versus Prednisolone acetate 1% eye drops following uneventful phacoemulsification surgery
Suez Canal University Hospital0 个研究点目标入组 800 人开始时间: 2022年7月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- Other
- 发起方
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45 Year(s) 至 64 Year(s)（—）
- 性别
- All
入选标准
- •1.Age more than 50 years
- •2.Patients diagnosed to have cataract, LOCS III cataract classification: NO = 2 and NC = 2)
排除标准
- •1.Known sensitivity to any of the ingredients in this study medication
- •2.History of glaucoma or ocular hypertension in the study eye
- •3.Previous history of steroid-induced increase of intraocular pressure (IOP)
- •4.Previous ocular surgery
- •5.history of uveitis
- •6.Intraoperative complications as posterior capsule rupture
- •7.Diabetic patients, Pregnancy, Autoimmune patients, and Single eyed patient.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19).The study population will consist of adults (18-80 years old) hospitalised for =48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test positive from nasopharyngeal swab. Patients with ARDS or patients requiring mechanical ventilation at screening or randomisation will be excludedMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002295-13-FRAssistance Publique - Hôpitaux Paris100
进行中（未招募）
1 期
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12
已完成
1 期
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN)M32.1Systemic lupus erythematosus with organ or system involvementDRKS00004858Charité - Universitätsmedizin Berlin10
进行中（未招募）
不适用
Assessment of the safety, efficacy, tolerability and pharmacokinetics of PegIntron plus Rebetol in pediatric patients with chronic hepatitis C.EUCTR2004-000558-22-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
已完成
3 期
A STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF LORNOXICAM SR 16mg Vs LORNOXICAM 8mg IN ADULT PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEECTRI/2009/091/000297Glenmark Pharmaceuticals Ltd.210